CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Download the Duo Mobile App to stay connected to UC systems
February 6, 2026
Students, faculty, and staff still using SMS text messaging or phone calls to authenticate with Duo need to switch to the Duo Mobile app as soon as possible to ensure uninterrupted access to UC systems. Learn more and find instructions under “How to switch from Text/Call to Duo Push” at uc.edu/2fa.
Will AI really replace your job?
February 6, 2026
As artificial intelligence seeps into more careers, some people wonder if any jobs will become obsolete in the coming years, according to 700WLW. Jeffrey Shaffer, director of Lindner College of Business’ Applied AI Lab, spoke with 700WLW on the future of AI in the workplace.
Revolutionary AI technology enhances diagnosis of substance use disorder
February 6, 2026
MSN, Bioengineer and other outlets highlight a new study by researchers at the University of Cincinnati who developed a novel AI to predict substance use disorder.